Pharmaceutical Business Review
Return to: PBR Home | Companies

Acura Pharmaceuticals Inc

Acura Pharmaceuticals Inc
Suite 120
616 N. North Court
United States of America
Phone: 1 847 7057709
Fax: 18-47-7055399

Turnover: 04.46 (US$m)
Financial year end: December

Company Overview

Top Competitors

Key Employees

Robert B. Jones

Chief Executive Officer, Director, President, Executive Board

George K. Ross

Director, Non Executive Board

Bruce F. Wesson

Director, Non Executive Board

William G. Skelly

Director, Non Executive Board

Immanuel Thangaraj

Director, Non Executive Board

Albert W. Brzeczko, Ph.D.

Vice President - Technical Affairs, Senior Management

Gregory A. Spinner

Director of Logistics and Special Projects, Senior Management

Robert A. Seiser

Vice President, Treasurer, Controller - Corporate, Senior Management

Ronald L. Leech

Senior Director Quality and Analytical Chemistry, Senior Management

John G. Gilkay

Director - EHS and Engineering, Senior Management

James F. Emigh

Vice President - Corporate Development, Senior Management

J. Bradley Rivet

Vice President - Marketing, Senior Management

Peter A. Clemens

Chief Financial Officer, Senior Vice President, Secretary, Senior Management


Suite 120,
616 N. North Court,
United States of America
Phone: 1 847 7057709
Fax: 1 847 7055399

United States of America

Acura Pharmaceutical Technologies Inc

16235 State Road 17,
United States of America
Phone: 1 574 8423305
Fax: 1 574 8422519



  • Marketed
  • Oxaydo (oxycodone HCl) tablets
  • Nexafed (pseudoephedrine HC1)
  • Nexafed Sinus Pressure
  • Pipeline
  • Limitx Technology:
  • Immediate-release hydromorphone HCI (LTX-04)
  • Immediate-release hydrocodone bitartrate with acetaminophen (LTX-03)
  • Immediate-release oxycodone HCl (LTX-01) & (LTX-02)
  • Impede Technology:
  • Nexafed 30mg
  • Immediate-release pseudoephedrine HCl
  • Extended-release combination products
  • Methamphetamine resistant pseudoephedrine